Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284970 · ClinicalTrials.gov registry record
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- 34
- Enrollment target
- 1
- Study location
NCT03284970 is a study of Relapsing Remitting Multiple Sclerosis that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 34 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03284970, a study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) counts and ratios in subjects aged 50 years and above with Relapsing-Remitting Multiple Sclerosis (RRMS).
Conditions Studied
Study Locations (1)
Massachusetts
- Neurology Center of New England - Foxborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2018-05-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03284970
The ClinicalTrials.gov registry entry for NCT03284970 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (83% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT03284970 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03284970 about?
NCT03284970 is a clinical study titled "Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes". This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) counts and ...
What is the current status of trial NCT03284970?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2017-08-23. Estimated completion is 2018-05-11.
What conditions does trial NCT03284970 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT03284970?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03284970 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.